Please assess the completion status of the following clinical trial:

Trial Title: Anti-inflammatory Effects of Simvastatin

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age: 18 to 75 years of age.~2. Obese (BMI ≥30 kg/m2)~3. LDL cholesterol of ≥100 mg/dl~4. Not taking any vitamins or antioxidants~Exclusion Criteria:~1. Currently using anti-hyperlipidemic therapies~2. Triglycerides \>500 mg/dl.~3. Myocardial infarction, angioplasty/stent placement or coronary artery bypass surgery in the past 6 months.~4. Patient on chronic use of non-steroidal anti-inflammatory drugs or steroids~5. Hepatic disease~6. Renal impairment.~7. History of drug or alcohol abuse~8. Participation in any other concurrent clinical trial~9. Use of an investigational agent or therapeutic regimen within 30 days of study.~10. Smoker~11. Pregnancy~12. Premenopausal women who are not on birth control pills and have not had a hysterectomy or tubal ligation~13. Anemia with hemoglobin \<12 g/dl

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Simvastatin (Type: ACTIVE_COMPARATOR): Obese subjects with elevated cholesterol
- Ezetimibe (Type: ACTIVE_COMPARATOR): Obese subjects with elevated cholesterol

Based on this trial design, predict the completion outcome and termination type (if applicable).